Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vatican Health Times.
Press releases published on August 28, 2025
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
GlobeNewswire
·
August 28, 2025
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA Outlook Therapeutics plans to work with FDA to address the Agency’s issues Company to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 ( …
KFSHRC Advances Nursing Excellence Through Specialized Training
GlobeNewswire
·
August 28, 2025
RIYADH, Saudi Arabia, Aug. 28, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital …
Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL
GlobeNewswire
·
August 28, 2025
HYDERABAD, India, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new …
ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, er nu kommercielt tilgængelig på laboratorier i USA gennem BioPortos samarbejde med Roche Diagnostics.
GlobeNewswire
·
August 28, 2025
28. august 2025 Meddelelse ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, er nu kommercielt tilgængelig på laboratorier i USA gennem BioPortos samarbejde med Roche Diagnostics. Samarbejdet med Roche Diagnostics markerer det første væ …
ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.
GlobeNewswire
·
August 28, 2025
August 28, 2025 News Release ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics. Collaboration with Roche Diagnostics is first major commercial …
TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation
GlobeNewswire
·
August 28, 2025
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung cancer (NSCLC) 1 in 5 cancer-related deaths in the US are …
Oculis to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
August 28, 2025
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet …
Dermatology Expert Laurel Leithauser, MD, FFAD, FACMS, Offers UV Protection and Skin Cancer Screening Advice in HelloNation
GlobeNewswire
·
August 28, 2025
TRAVERSE CITY, Mich., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Why should residents in Traverse City treat a skin cancer screening like any other annual health exam? In HelloNation, Dr. Laurel Leithauser of Leithauser Skin Institute explains why routine checkups …
Veterinary Expert Dr. Ben Nemmers Explains What Most People Don’t Realize About Boarding with Vet Care in HelloNation
GlobeNewswire
·
August 28, 2025
CEDAR FALLS, Iowa, Aug. 28, 2025 (GLOBE NEWSWIRE) -- What makes pet boarding with veterinary care different from a standard kennel stay? In HelloNation, Dr. Ben Nemmers of Companion Animal Clinic …
argenx to Present at Upcoming Investor Conferences
GlobeNewswire
·
August 28, 2025
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext …
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
GlobeNewswire
·
August 28, 2025
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for …
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
GlobeNewswire
·
August 28, 2025
- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - PURCHASE, N.Y., Aug. 27, 2025 (GLOBE …